Trial · NCT05470985
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Who Achieve Pediatric Crohn's Disease Activity Index (PCDAI) < 10 at Week 12 Based on Data as Observed | Ozanimod 0.92 mg | 0 | Percentage of participants | ||
| Percentage of Participants Who Achieve Simple Endoscopic Score for Crohn's Disease (SES-CD) Decrease From Baseline of ≥ 50% (ER-50) at Week 12 Based on Data as Observed | Ozanimod 0.92 mg | 0 | percentage of participants | ||
| Percentage of Participants Who Achieve Reduction in Pediatric Crohn's Disease Activity Index (PCDAI) Score ≥ 12.5 and a Total PCDAI Score of < 30 Points at Week 12 Based on Data as Observed | Ozanimod 0.92 mg | 0 | percentage of participants | ||
Percentage of Adolescents Who Achieve an Average Daily Abdominal Pain Score ≤ 1 Point and an Average Daily Stool Frequency ≤ 3 Points With Abdominal Pain and Stool Frequency no Worse Than Baseline at Week 12 Based on Data as Observed | Ozanimod 0.92mg | 0 | percentage of participants | ||
| Percentage of Adolescents Who Achieve Crohn's Disease Activity Index (CDAI) Score < 150 at Week 12 Based on Data as Observed | Ozanimod 0.92mg | 0 | percentage of participants | ||
| Percentage of Adolescents Who Achieve Crohn's Disease Activity Index (CDAI) Reduction From Baseline of ≥ 100 Points or CDAI Score < 150 at Week 12 Based on Data as Observed | Ozanimod 0.92mg | 0 | percentage of participants | ||
| Percentage of Participants Achieving Simple Endoscopic Score for Crohn's Disease (SES-CD) ≤ 2 or SES-CD ≤ 4 Points With no SES-CD Subscore > 1 Point at Week 12 Based on Data as Observed | Ozanimod 0.92mg | 0 | percentage of participants | ||
| Absolute Lymphocyte Count at Week 12 Based on Data as Observed | Ozanimod 0.92mg | 0.66 | Standard Deviation NA | 10^9 cells per liter | |
| Number of Participants With Adverse Events | Ozanimod 0.46 mg | Adverse Events | 3 | Participants | |
| Number of Participants With Adverse Events | Ozanimod 0.92mg | Adverse Events | 2 | Participants | |
| Number of Participants With Adverse Events | Ozanimod 0.46 mg | Serious Adverse Events | 0 | Participants | |
| Number of Participants With Adverse Events | Ozanimod 0.92mg | Serious Adverse Events | 0 | Participants | |
| Number of Participants With Adverse Events | Ozanimod 0.46 mg | Adverse events leading to Discontinuation | 0 | Participants | |
| Number of Participants With Adverse Events | Ozanimod 0.92mg | Adverse events leading to Discontinuation | 0 | Participants | |
| Number of Participants With Adverse Events | Ozanimod 0.46 mg | Adverse Events of Special Interest | 0 | Participants | |
| Number of Participants With Adverse Events | Ozanimod 0.92mg | Adverse Events of Special Interest | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05470985/results